Neuroendocrine Neoplasm Clinical Trial
— DOBATOCOfficial title:
Dosimetry Based PRRT Versus Standard Dose PRRT With Lu-177-DOTATOC in NEN Patients- a Randomized Study; a Step Towards Tailored PRRT
In this study, we want to randomize patients with neuroendocrine neoplasms (NENs) who are eligible for peptide receptor radionuclide therapy (PRRT), to either standard PRRT consisting of 4 treatments with 7.4 GBq Lu-177-DOTATOC (standard arm) or 4 treatments with individualized doses of Lu-177-DOTATOC (dosimetry arm). In the dosimetry arm, the first dose depends on the patients' kidney function and thereafter the absorbed dose to the kidneys at the previous treatment. A max of 20GBq will be administered at the first treatment and 25GBq at treatment 2-4. We aim to reach an accumulated kidney dose of 24Gy. After the first treatment all patients will go through three SPECT/CT scans 24 hours, 4 days, and 7 days, after treatment to calculate absorbed kidney dose. The patients in the standard dose treatment arm will have one SPECT/CT scan after each of the last three treatments; all performed 24 hours after treatment, used to approximate the kidney dose assuming the clearance of the Lu-177 DOTATOC is the same after all treatments. The patients in the dosimetry based treatment arm will go through three SPECT/CT scans after all four treatments for dosimetry calculation. Bone marrow dosimetry is calculated after all treatments in the dosimetry based treatment arm and after the first treatment in the standard treatment arm. For bone marrow dosimetry, blood samples are drawn right before administration of Lu-177 DOTATOC (time 0) and 3 minutes, 45 minutes, 2 hours, 4 hours, 7-8 hours, 24 hours, 4 days, and 7 days after administration of Lu-177 DOTATOC. Standard blood samples are routinely drawn every 2nd week after every treatment in all included patients and analysed regarding liver, kidney and bone marrow function. Kidney clearance is evaluated with Tc-DTPA clearance at baseline. Blood and urinary samples will be collected at baseline and 3 months after the last treatment for kidney fibrosis analyses. At baseline, blood and urine samples are collected for a biobank. All included patients fill in validated quality of life questionaires at all treatments. To evaluate the effect of the treatment, all patients will be evaluated with standard CT scans prior to treatment and 3 and 9 months after the 4th treatment. Ga-68 DOTATOC PET will be performed at baseline and 6 and 12 months after the last treatment.
Status | Recruiting |
Enrollment | 100 |
Est. completion date | December 2026 |
Est. primary completion date | December 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - 1. Male or female patients 18 years of age or more - 2. NEN confirmed by histology - 3. Clinical, PET/CT or CT proven progression despite standard treatment with somatostatin analogues, targeted therapy (Everolimus, sunitinib), chemotherapy (STZ/5-FU, temozolomide/capecitabine) OR intolerable side effects caused by these standard treatment OR unmanageable carcinoid symptoms - 4. WHO/ ECOG Performance Status of 0-2 - 5. Life expectancy more than 6 months - 6. Uptake higher than liver in primary tumor or metastases on Ga-DOTATOC PET/CT (Krenning 3 or 4), if the scan is more than 3 months old at inclusion time, a new scan should be done. - 7. Adequate organ function as defined by: - Adequate kidney function: Patient glomerular filtration rate >30 ml/min measured by Tc-DTPA clearance - Adequate bone marrow function: - WBC = 2.0 x 109/L - Platelets = 100 x 109/L - Hb = 6 mmol/l (=9.67 g/dL) - 8. Willingness and ability to comply with scheduled visits for SPECT/CT scans, treatment plans, laboratory tests and other study procedures. 9. Written informed consent obtained prior to any screening procedures Exclusion Criteria: - 1. Tumor amenable to surgery and/or radiofrequency ablation - 2. Patients who are unable to stay isolated for 24 hours - 3. Previous PRRT - 4. Female patients who are pregnant or lactating. Women who are of childbearing potential (defined as all women physiologically capable of becoming pregnant) have to practice an effective method of contraception/birth control. Fertile female patients have to take a urinary pregnancy test, to ensure that they are not pregnant, before they can enter the study. After entering the study, they have to use effective contraception during the study period and 6 months after. Effective contraception methods include: - Use of oral, injected or implanted hormonal methods of contraception or - Placement of an intrauterine device (IUD) or intrauterine system (IUS) - Total abstinence or patient sterilization (male or female) - 5. Male patients are not allowed to conceive pregnancy for 6 months after last treatment cycle - 6. Known to be hypersensitive to any component of the Lu-177-DOTATOC - 7. Patients with meningioma |
Country | Name | City | State |
---|---|---|---|
Denmark | Aarhus University Hospital, department of Nuclear medicine and PET centre | Aarhus | Palle Juul-Jensens Boulevard |
Lead Sponsor | Collaborator |
---|---|
Tine Gregersen, MD |
Denmark,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Kidney toxicity | Measured by Tc-DTPA clearance | At baseline and after 3, 6 and 12 months | |
Other | Kidney toxicity | Measured by kidney fibrosis markers PRO-C6, PRO-C3, and C3M two groups | At baseline and 3 months after the last treatment | |
Other | Bone marrow function, hemoglobin | Measured by hemoglobin in the two groups | Every second week in up to 64 weeks | |
Other | Bone marrow function, white blood cells | Measured by white blood cells in the two groups | Every second week in up to 64 weeks | |
Other | Bone marrow function, platelets | Measured by platelets in the two groups | Every second week in up to 64 weeks | |
Other | Subjective side effects | Evaluated by use of dedicated questionaire with score from 0-3 | After every treatment, up to 48 weeks | |
Other | Quality of life score 1 | Evaluated by questionnaire EORTC QLQ-30 filled out at every treatment | After every treatment, up to 48 weeks | |
Other | Quality of life score 2 | Evaluated by questionnaire QLQ-GI.NET21. filled out at every treatment | After every treatment, up to 48 weeks | |
Other | Overall survival | Registration of time for baseline to death | 3 years after LPLV | |
Primary | Progression free survival | Defined as time from randomization to documented disease progression or death by any cause, evaluated by CT, RECIST 1.1. | 12 months after LPLV | |
Secondary | Tumor dose | Difference in tumor dose between dosimetry based and standard PRRT treatment groups and between patients in the dosimetry based treatment group over time. | Through out the study efter each patient has completed treatment, up to 48 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04464122 -
Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN)
|
||
Active, not recruiting |
NCT03375320 -
Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
|
Phase 3 | |
Active, not recruiting |
NCT03980925 -
Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.
|
Phase 2 | |
Recruiting |
NCT02402244 -
Project: Every Child for Younger Patients With Cancer
|
||
Recruiting |
NCT05113355 -
Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm
|
Phase 2 | |
Recruiting |
NCT05879055 -
A Study of PM8002 Injection in Combination With Chemotherapy in Patients With NEN
|
Phase 2 | |
Terminated |
NCT03001349 -
68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors
|
Early Phase 1 | |
Completed |
NCT02399215 -
Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
|
Phase 2 | |
Recruiting |
NCT05165407 -
Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC
|
Phase 2 | |
Recruiting |
NCT06337760 -
YOUNg Adults With Gastro-inteSTinal (GI) and nEuroendocrine canceRs.
|
||
Recruiting |
NCT04927611 -
Single-cell Sequencing and Establishment of Models in Neuroendocrine Neoplasm
|
||
Active, not recruiting |
NCT01638533 -
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
|
Phase 1 | |
Recruiting |
NCT02817945 -
Dual SSTR2 and Integrin αvβ3 Targeting PET/CT Imaging
|
Early Phase 1 | |
Active, not recruiting |
NCT03950609 -
Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors
|
Phase 2 | |
Active, not recruiting |
NCT04750954 -
Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors
|
Phase 1 | |
Active, not recruiting |
NCT02402920 -
Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer
|
Phase 1 | |
Not yet recruiting |
NCT04931446 -
Neuroendocrine Neoplasm Based on Multi-omics Integrated Analysis
|
||
Recruiting |
NCT06343428 -
Definition of a Multiparametric Prognostic and Predictive System of Classification of NET G3 Patients
|
||
Recruiting |
NCT04720391 -
Bone Metastases in neurOendocrine NEoplasms: naTural History, Prognostic Impact and Therapeutic Approach (MONET)
|
||
Recruiting |
NCT03734913 -
A Phase 1 Study of ZSP1602 in Participants With Advanced Solid Tumors
|
Phase 1 |